Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × enzalutamide × Clear all

Phase

Phase 2 58 Phase 1 26 Phase 4 9 Phase 3 8 Phase 1/2 6 Phase NA 1 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Active not recruiting 2 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Cisplatin 19 Fluorouracil 17 Gemcitabine 14 Radiotherapy 13 Paclitaxel 13 Docetaxel 13 Oxaliplatin 12 Cyclophosphamide 11 Carboplatin 11 Capecitabine 11 Bevacizumab 11 Drug Therapy 10 Leucovorin 9 Cytarabine 9 Irinotecan 8 Magnetic Resonance Spectroscopy 7 Dexamethasone 7 Saline Solution 6 Methotrexate 6 Letrozole 6 Exercise 6 Etoposide 6 pembrolizumab 5 Rituximab 5 Nivolumab 5 Melphalan 5 Lidocaine 5 Filgrastim 5 Electroporation 5 Doxorubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡